











































As	 well	 as	 ethnicity,	 other	 factors	 appear	 to	 influence	 lung	 cancer	 susceptibility.	 Gender	 is	 another	
important	demographic	that	influences	lung	cancer	risk	and	certainly	it	has	been	suggested	that	the	cost	
effectiveness	 of	 lung	 cancer	 screening	 is	 far	 higher	 in	women	 compared	with	men	 (ICER	 $46,000	 vs.	
$147,000	(3)).		Furthermore,	 as	well	 as	 COPD,	 other	 comorbidities	 also	 increase	 susceptibility	 to	 lung	
cancer	 through	 varying	mechanisms.	 Certainly,	 HIV	 and	 idiopathic	 pulmonary	 fibrosis	 have	 also	 been	
associated	with	a	higher	risk	of	lung	cancer	even	after	accounting	for	smoking	history(4,	5). 
	 
Another	 interesting	 observation	 is	 that	 interval	 cancers	 in	 the	 NELSON	 study	 were	 associated	 with	
increased	 age,	 though	 not	 smoking	 status(6).	 Apart	 from	 this	 study,	 very	 little	 is	 known	 about	 the	




The	 relationship	 between	 individual	 lung	 cancer	 risk,	 lung	 cancer	 detection,	 survival	 benefit	 of	 the	
screened	 population	 and	 cost-effectiveness	 of	 lung	 cancer	 screening	 is	 complex.	 The	 current	 USPSTF	
criteria(7)	for	screening	eligibility	are	reasonable	at	this	time,	but	are	likely	to	be	adapted	in	the	future,	
given	the	growing	evidence	base	that	will	in	due	course	inform	the	medical	communities	on	how	best	to	
optimise	 the	 harms	 and	 benefits	 of	 lung	 cancer	 screening	 in	 individuals	 with	 varying	 risk	 profiles.	
Screening	 may	 be	 appropriate	 at	 alternative	 age	 and	 risk	 thresholds,	 or	 at	 more	 or	 less	 frequent	
intervals	 in	 certain	 groups.	 Lung	 cancer	 risk	 and	 detection	 rate	 both	 need	 to	 be	 balanced	 with	
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